Zhang L, Yu WJ, Zhu H, Li HF, Qiao J. Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. World J Clin Cases 2022; 10(21): 7495-7501 [PMID: 36158023 DOI: 10.12998/wjcc.v10.i21.7495]
Corresponding Author of This Article
Jie Qiao, MD, PhD, Chief Doctor, Department of Endocrinology, Shanghai Jiaotong University School of Medicine, Shanghai 9th Hospital, No. 369 Zhizaoju Road, Shanghai 200011, China. qiaoj2001@126.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2022; 10(21): 7495-7501 Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7495
Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report
Lei Zhang, Wen-Juan Yu, Hui Zhu, Hua-Fang Li, Jie Qiao
Lei Zhang, Wen-Juan Yu, Hua-Fang Li, Department of Psychiatry, Shanghai Mental Health Center, Shanghai 200030, China
Lei Zhang, Wen-Juan Yu, Hui Zhu, Hua-Fang Li, Jie Qiao, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
Hui Zhu, Jie Qiao, Department of Endocrinology, Shanghai Jiaotong University School of Medicine, Shanghai 9th Hospital, Shanghai 200011, China
Author contributions: Zhang L performed the disease consultation, acquired the clinical data, and drafted the manuscript; Yu WJ and Zhu H reviewed the literature; Qiao J and Li HF edited and reviewed the manuscript.
Supported bythe National Natural Science Foundation of China, No. 81873652; and the Programs Foundation of Shanghai Mental Health Center, China, No. 2020-QH-03.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Qiao, MD, PhD, Chief Doctor, Department of Endocrinology, Shanghai Jiaotong University School of Medicine, Shanghai 9th Hospital, No. 369 Zhizaoju Road, Shanghai 200011, China. qiaoj2001@126.com
Received: December 30, 2021 Peer-review started: December 30, 2021 First decision: February 8, 2022 Revised: February 24, 2022 Accepted: June 3, 2022 Article in press: June 3, 2022 Published online: July 26, 2022 Processing time: 192 Days and 16.4 Hours
Abstract
BACKGROUND
Antipsychotics are associated with abnormalities in glucose metabolism in patients with schizophrenia. Liraglutide, a GLP-1 receptor agonist, is Food and Drug Administration approved for the treatment of type 2 diabetes mellitus. However, ways to maintain the long-term stability of psychotic symptoms and balance the disadvantages of obesity, diabetes, and other metabolic disorders caused by antipsychotic medications remain unclear. In this study, we present a case of weight gain and hyperglycemia in a schizophrenia patient who received antipsychotic polypharmacy for 6 years.
CASE SUMMARY
A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic. He was diagnosed with type 2 diabetes (fasting blood glucose, 20 mmol/L) and obesity (body mass index, 38.58 kg/m2). The patient had been treated with glargine (40 IU/d) and metformin (1.5 g/d) and showed a poor response for 2 mo. Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time. The biological activities of GLP-1 significantly improved glucose levels and body weight in the schizophrenia patient treated with antipsychotic medications.
CONCLUSION
Liraglutide administration can be considered an effective alternative treatment for abnormalities in glucose metabolism in schizophrenia patients receiving antipsychotics.
Core Tip: This report describes the effects of GLP-1 receptor agonist treatment in a young schizophrenia patient with long-term use of antipsychotics, which induced type 2 diabetes. It presents the success of blood glucose control with the GLP-1 receptor agonist in a short period of time during his hospitalization and helped him to control his blood glucose and lose weight while maintaining a stable mental status in the long-term.
